2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease

关于 BACE 蛋白酶在健康和疾病中的作用的第二届 Kloster Seeon 会议

• 批准号: 9195559
• 负责人: ROBERT J VASSAR
• 金额: $ 3.4万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9195559
• 关键词: Academia; Advanced Development; Adverse effects; Air; Alzheimer disease prevention; Alzheimer' s Disease; Amyloid beta-Protein; Amyloid beta-Protein Precursor; Animal Model; Area; Aspartic Endopeptidases; Award; Behavior; Biochemical; Biological; Brain; Case Study; Cells; Cerebrum; Cleaved cell; Clinical; Clinical Trials; Communities; Complex; Development; Disease; Disease Progression; Enzymes; Fostering; Funding; Genetic; Germany; Goals; Health; Human; Industry; International; Internet; Journals; Knockout Mice; Knowledge; Laboratories; Location; Mutation; Nervous System Physiology; Neurites; Neurosciences; Paper; Pathogenesis; Peptide Hydrolases; Pharmaceutical Preparations; Physiological; Postdoctoral Fellow; Process; Production; Publications; Publishing; Reading; Regulation; Reporter; Reporting; Research; Research Personnel; Retinal; Risk; Role; Safety; Science; Scientist; Senile Plaques; Senior Scientist; Site; Staging; Students; Therapeutic; Toxic effect; Training; Travel; United States National Institutes of Health; Universities; Writing; abeta accumulation; abstracting; amyloid peptide; base; beta secretase; beta-site APP cleaving enzyme 1; cost; drug development; experience; graduate student; improved; inhibitor/antagonist; lectures; meetings; novel; peptide A; posters; prevent; professional atmosphere; programs; research and development; secretase; success; symposium; therapeutic target; transmission process; web site

Project Summary Compelling genetic, biochemical, cell biological, animal model, and human studies suggest that cerebral accumulation of the -amyloid peptide (A) has a critical early role in Alzheimer's disease (AD) pathogenesis. The -secretase enzyme BACE1 is the rate-limiting enzyme for A production. Thus, BACE1 is a prime therapeutic target for the treatment or prevention of AD. Several BACE1 inhibitor drugs for AD are in clinical trials, but the safety and efficacy of these agents are unknown. The BACE proteases field comprises very active and diverse areas of research that have high impact on therapeutic approaches to treat and prevent AD. Here, I propose the 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease, September 25-27, 2016, in Bavaria, Germany, which has the following objectives: 1) disseminate the latest information on BACE proteases research and catalyze discussion among scientists in academia and industry, 2) promote the training of young scientists, and 3) publish a state-of-the-art review of BACE research to help advance the field and facilitate the development of safe and effective BACE inhibitor drugs for AD. The Scientific Program consists of: 1) a Keynote Lecture by Dr. Kari Stefansson (DeCode Genetics), who recently discovered a mutation in APP that protects against AD by reducing BACE1 cleavage, thus providing proof of concept for therapeutic BACE1 inhibition, 2) two full days of sessions comprising 25-minute talks from 24 leading experts in the BACE proteases field, 3) a session of 2-minute flash talks given by 10 selected graduate students and post-doctoral researchers to introduce their posters, 4) poster sessions on each of two evenings that will enhance the training experience of students and post-docs, 5) a panel discussion between academic and industry scientists on the current state of BACE research and drug development, 6) a conclusion and summary session to remark on the meeting and discuss the direction forward for the field. This meeting is co-organized by Drs. Stefan Lichtenthaler (Technical University Munich) and Robert Vassar (Northwestern University), two leading scientists in the BACE proteases field. The 1st Kloster Seeon Meeting on BACE Proteases in Health and Disease was held at the same location on October 6-8, 2013, and was objectively successful at disseminating the latest BACE research and catalyzing discussion among BACE scientists. Three years have passed, and significant advances in BACE research have been made, including new clinical trials, discoveries of novel BACE1 substrates and functions, different mechanisms of BACE regulation in health and dysregulation in AD, and identification of new proteolytic activities. Given these new advances, the 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease is timely and important for dissemination of the latest information in the field. Additionally, no other scientific meeting or conference focuses exclusively on BACE proteases research, making this meeting a unique scientific forum that will contribute significantly to the advancement of the AD research and drug development fields.

项目摘要 令人信服的遗传学、生化、细胞生物学、动物模型和人类研究表明，大脑 -淀粉样多肽(A-)的积聚在阿尔茨海默病(AD)的发病机制中起着关键的早期作用。 分泌酶BACE1是A-合成的限速酶。因此，BACE1是一个素数 治疗或预防阿尔茨海默病的治疗目标。几种治疗阿尔茨海默病的BACE1抑制剂药物正在临床 试验，但这些药物的安全性和有效性尚不清楚。BACE蛋白酶领域包括非常多的 积极和多样化的研究领域，对治疗和预防阿尔茨海默病的方法有很大影响。 在此，我提议于9月25日至27日召开第二次Kloster Seeon会议，讨论BACE蛋白在健康和疾病中的作用， 2016年，在德国巴伐利亚州，其目标如下：1)传播关于BACE的最新信息 研究和催化学术界和工业界科学家之间的讨论，2)促进 培训年轻科学家，以及3)发表一篇关于BACE研究的最新评论，以帮助推动该领域的发展 为开发安全有效的治疗AD的BACE抑制剂药物提供便利。科学纲领 包括：1)由Kari Stefansson博士(解码遗传学)发表的主旨演讲，他最近发现了一个 APP中的突变通过减少BACE1裂解来预防AD，从而为 治疗性BACE1抑制，2)为期两天的会议，包括来自24位领先专家的25分钟演讲 在BACE蛋白酶领域，3)由10名精选的研究生和 博士后研究人员介绍他们的海报，每两个晚上都举行海报会议，这将 增强学生和博士后的培训体验，5)学术和博士后小组讨论 业界科学家对BACE研究和药物开发的现状，6)结论和总结 会议对会议发表评论，并讨论该领域的前进方向。这次会议是联合组织的。 作者：斯特凡·利希滕塔勒博士(慕尼黑工业大学)和罗伯特·瓦萨博士(西北大学)，两位 BACE蛋白水解酶领域的领先科学家。第一届Kloster Seeon关于BACE蛋白酶与健康的会议 和疾病于2013年10月6日至8日在同一地点举行，客观上成功地在 传播BACE的最新研究成果，并促进BACE科学家之间的讨论。三年来， 通过，在BACE研究方面取得了重大进展，包括新的临床试验、发现 新的BACE1底物和功能，不同的BACE调节机制在健康和 AD中的失调，以及新的蛋白水解酶活性的鉴定。鉴于这些新进展，第二克罗斯特 关于BACE蛋白在健康和疾病中的作用的会议对于传播 该领域的最新信息。此外，没有其他科学会议或会议专门关注 BACE蛋白酶研究，使这次会议成为一个独特的科学论坛，将对 AD研究和药物开发领域的进展。